作者:Angelo Ranise、Andrea Spallarossa、Silvia Schenone、Olga Bruno、Francesco Bondavalli、Alessandra Pani、Maria Elena Marongiu、Valeria Mascia、Paolo La Colla、Roberta Loddo
DOI:10.1016/s0968-0896(03)00158-5
日期:2003.6
12a-c,g-j, 13e,f,h and 14k were inactive. Cytotoxicity data provided from N.C.I. on selected compounds provided evidence that 11b,d, 13d,g and 14b,d,f,h,i,j were endowed with potent antiproliferative activity against leukemia and prostate cell lines (GI(50) up to 0.01 microM). In general, bicyclic derivatives 14 were up to 10-fold more potent than monocyclic counterparts against solid tumor-derived cell
合成了三个系列的5个取代的1,3-二苯基-6-(ω-二烷基-和ω-环氨基烷基)硫代-2-硫代巴比妥酸酯(11-13)作为Merbarone的多取代硫代类似物,merbarone是一种作用于拓扑异构酶II的抑制剂催化部位。为了更好地理解药效基团的需求,还制备了第四系列构象受限的类似物14。衍生物11b,e,14b,e,h,i,j在低微摩尔浓度范围内具有活性(IC(50):3.3-4.3 microM),而化合物11a,c,d,f,h,j和13a, b,d,g,j和14a,d,f显示的IC(50)值介于10和15.5 microM之间。相反,化合物12a-c,gj,13e,f,h和14k没有活性。NCI提供的有关选定化合物的细胞毒性数据提供了证据,表明11b,d,13d,g和14b,d,f,h,i,j被赋予针对白血病和前列腺细胞系的有效抗增殖活性(GI(50)高达0.01 microM)。通常